| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178563 | SUN PHARM | Compounds and compositions as hedgehog pathway modulators |
Jul, 2029
(5 years from now) | |
| US8063043 | SUN PHARM | Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide |
Sep, 2029
(5 years from now) | |
| US10266523 | SUN PHARM | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof |
Mar, 2036
(11 years from now) | |
Odomzo is owned by Sun Pharm.
Odomzo contains Sonidegib Phosphate.
Odomzo has a total of 3 drug patents out of which 0 drug patents have expired.
Odomzo was authorised for market use on 24 July, 2015.
Odomzo is available in capsule;oral dosage forms.
Odomzo can be used as treatment of basal cell carcinoma.
Drug patent challenges can be filed against Odomzo from 25 July, 2019.
The generics of Odomzo are possible to be released after 30 March, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
Drugs and Companies using SONIDEGIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of basal cell carcinoma
Dosage: CAPSULE;ORAL
More Information on Dosage
ODOMZO family patents
